NCT06097962 2026-03-20
Safety and Efficacy of NK510 to Treat NSCLC
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
Clinical Trials
10 trialsNCT05700448 2026-02-05
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
CStone Pharmaceuticals
Phase 3 Not yet recruiting
NCT07247227 2025-11-25
Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC
Peking Union Medical College
Phase NA Recruiting
NCT06617416 2025-03-12
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
Akeso
Phase 3 Recruiting
NCT06217757 2024-05-13
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Sichuan University
Phase 1/2 Recruiting
NCT06031597 2023-09-13
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
Zhejiang Cancer Hospital
Phase 3 Unknown
NCT05623267 2023-08-07
SURPASS
Sun Yat-sen University
Phase 2/3 Recruiting
NCT05940532 2023-07-11
A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
Hunan Cancer Hospital
Phase 2 Recruiting
NCT05131438 2023-03-27
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
EQRx International, Inc.
No longer available
NCT04194801 2023-02-06
A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma
CStone Pharmaceuticals
Phase 1/2 Completed